SION - NASDAQ
Sionna Therapeutics, Inc.
$37.38
+1.8%Sionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator.
At a Glance
Live Snapshotsion
Total Non-Current Liabilities
Last Annual Value
7.41M
3-Year CAGR
-63%
5-Year CAGR
-45%
10-Year CAGR
-26%
Sionna Therapeutics, Inc. Competitors Analysis of Total Non-Current Liabilities
| Company | Total Non-Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Sionna Therapeutics, Inc. NASDAQ:SION | 7.41M | -64.0% | N/A | N/A | |
 Vera Therapeutics, Inc. NASDAQ:VERA | 76.76M | 14.2% | 64.0% | N/A | |
 Janux Therapeutics, Inc. NASDAQ:JANX | 25.70M | 3.7% | 105.6% | N/A | |
 Maze Therapeutics, Inc. NASDAQ:MAZE | 19.61M | -24.3% | N/A | N/A | |
 Ardelyx, Inc. NASDAQ:ARDX | 246.05M | 45.2% | 76.2% | 77.8% | |
 Celldex Therapeutics, Inc. NASDAQ:CLDX | 4.83M | -3.3% | -11.0% | -24.7% | |
 Immunome, Inc. NASDAQ:IMNM | 3.85M | -17.4% | 217.2% | N/A | |
 Xeris Biopharma Holdings, Inc. NASDAQ:XERS | 260.26M | 3.6% | 14.9% | 15.3% | |
 Biohaven Ltd. NYSE:BHVN | 283.44M | 111.8% | 120.5% | N/A |
Sionna Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your SION research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.